Edition:
United States

Profile: Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

3.47GBp
2 Dec 2016
Change (% chg)

0.00p (+0.00%)
Prev Close
3.50p
Open
3.50p
Day's High
3.50p
Day's Low
3.40p
Volume
7,212,129
Avg. Vol
3,791,731
52-wk High
8.45p
52-wk Low
2.98p

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.

Company Address

Oxford BioMedica PLC

Windrush Court, Transport Way
OXFORD     OX4 6LT
P: +441865.783000
F: +441865.783001

Company Web Links